Exercise for Neuropathic Pain: A Systematic Review and Expert Consensus.

Neuropathic pain, the nerve-related pain that follows conditions like stroke, spinal cord injury, or chemotherapy, can be hard to manage and often limits movement and mood. This paper asked whether exercise therapy has any role across the many different diseases where neuropathic pain occurs, since guidance had been scattered and disease-specific. The authors systematically reviewed existing systematic reviews and randomized controlled trials, then had a panel of 21 rehabilitation experts debate the findings through a Delphi consensus process to produce 10 recommendations, one for each of 10 conditions including stroke, multiple sclerosis, diabetic neuropathy, and sciatica.

Overall, the available evidence suggested exercise could help reduce pain intensity in these populations, with exercise types ranging from stretching and resistance training to Tai Chi and yoga. The main limitation is that only eight systematic reviews and 21 trials underpinned the whole project, meaning the evidence behind each individual disease-specific recommendation is limited and consensus opinion filled gaps where trial data were thin.

If you live with nerve pain, sometimes called neuropathic pain, from a condition such as stroke, spinal cord injury, diabetes, or cancer treatment, this paper looked at whether exercise might help. Researchers gathered existing research studies and then had a group of 21 rehabilitation experts discuss the findings together to create practical recommendations for 10 different conditions linked to nerve pain. The overall picture is that exercise, including things like stretching, strength training, aerobic activity, balance-focused exercises, and mind-body practices like Tai Chi or yoga, appeared to help ease pain intensity in several of these conditions.

This is useful because exercise is low cost and widely accessible compared to many other pain treatments. It is worth understanding that this conclusion rests on a relatively small collection of research, only eight review papers and 21 individual trials, covering ten quite different health conditions. That means the evidence for any single condition, say diabetic neuropathy versus multiple sclerosis, may be thinner than the overall consensus suggests, and expert judgment filled in where strong trial evidence was lacking.

This is a summary of research, not medical advice. Talk to your own healthcare provider about anything affecting your care.

This paper addresses a practical gap many physiotherapists encounter: there has been no unified, disease-spanning synthesis of exercise evidence for neuropathic pain, forcing clinicians to extrapolate across conditions like spinal cord injury, Parkinson's disease, cervical radiculopathy, HIV-related neuropathy, and chemotherapy-induced peripheral neuropathy. The authors combined a systematic review of 8 systematic reviews and 21 randomized controlled trials with a Delphi consensus process involving 21 experts from the Chinese Association of Rehabilitation Medicine, producing 10 condition-specific recommendations covering stretching, resistance and aerobic exercise, motor control or stabilization training, and mind-body approaches such as Tai Chi and yoga. For clinical reasoning, this informs the plausibility that exercise, broadly construed, may have a role in neuropathic pain management across multiple diagnoses, rather than confirming a specific protocol, dose, or exercise type as superior for any one condition.

The recommendations are graded through quality assessment tools (PEDro and AMSTAR) and strength-of-evidence grading, but the abstract does not report pooled effect sizes, confidence intervals, or heterogeneity statistics, so the precision and consistency of benefit across studies cannot be judged from what is given. What this does not establish is efficacy for any single disease population with strong certainty, since each of the 10 disease-specific recommendations rests on a fraction of the total 8 reviews and 21 trials, and the abstract does not specify study designs within the reviews beyond RCTs and systematic reviews being eligible. Adverse events are not mentioned in the abstract, so no safety conclusions can be drawn.